INTRODUCTION
The increased renal venous renin activity first observed in patients with congestive heart failure by Merrill et al. (1) 30 years ago, suggested that renin may play a role in the maintenance of blood pressure in cardiac failure. Several years before aldosterone was identified, Deming and Luetscher (2) also reported that patients with congestive failure excreted increased amounts of a saltretaining steroid, now known to be aldosterone. However, the plasma levels of renin and aldosterone in patients and experimental animals with congestive heart failure have subsequently been reported as high, low, or normal (3) (4) (5) (6) (7) (8) (9) . As a result of this variability, the role of the renin-angiotensin-aldosterone (RAA)1 system in the syndrome has not been clearly defined.
The recent availability of inhibitors of the reninangiotensin system, as well as an appropriate animal model, has provided means for a more precise analysis of the problem. Congestive failure has been induced in the conscious trained dog by inflation of a previously implanted constricting cuff around the thoracic inferior vena cava (TIVC) or the pulmonary artery. The response of the RAA system was monitored from the time of constriction to the development of frank congestive failure, thus enabling us to study the sequence of events in the progressive course of the disease uncomplicated by anesthesia and surgery. Pulmonary artery stenosis in the dog produces a right-sided congestive heart failure similar to that seen in man, with cardiac enlargement, elevated right ventricular end diastolic pressure, low cardiac output, inability to exercise, and retention of sodium and water with resultant ascites and edema. TIVC constriction, although not a model of cardiac failure, simulates the hemodynamic consequences of impaired cardiac performance (10, 11) . By the use of the nonapeptide converting enzyme inhibitor (CEI) (12) (13) (14) which blocks the conversion of angiotensin I to the physiologically active pressor agent angiotensin II, we have been able to assess quantitatively the role of the RAA system in the regulation of systemic pressure during the development of congestive failure. We have also examined the role of the renin-angiotensin system in the regulation of plasma aldosterone levels, sodium excretion, and water balance. Finally, the nonapeptide has enabled us to show that the ability of the animals to compensate for the circulatory impairment imposed by constriction is markedly impaired if the generation of angiotensin II and the rise in plasma aldosterone is suppressed.
METHODS
Mongrel dogs (20-30 kg) were kept in metabolic cages in a room of constant temperature and fed a fixed diet containing approximately 75 meq of sodium and of potassium.
Free access to water was allowed and 24-h intake and urinary output measured. The animals were trained to lie quietly on a padded table in an air-conditioned room. After training the animals were prepared surgically for the experiments.
Surgical procedures
For surgical procedures the animals were anesthetized with intravenous pentobarbital sodium (30 mg/kg). Under sterile conditions, with the animal on artificial ventilation, thoracotomy was performed through the left 4th intercostal space. The pericardial sac was opened widely exposing the pulmonary artery and the TIVC. A 2.0 X 1.5-cm inflatable silastic rubber cuff was placed around the main pulmonary artery and a 2 X 2-cm cuff was placed around the TIVC. A polyvinyl chloride catheter (0.04 inch ID, 0.07 inch OD) was placed in the right atrium through the atrial appendage; in several dogs a catheter was also implanted in the left atrium. The abdominal aorta and vena cava were approached retroperitoneally through a left flank incision and were catheterized with polyvinyl chloride catheters (0.025 inch ID, 0.056 inch OD) using the techniques of Herd and Barger (15) . The intravascular catheters and the catheters attached to the inflatable cuffs were exteriorized through subcutaneous tunnels over the left flank and protected by a cotton jacket. The animals were allowed to recover for 2 wk before experiments were started.
Experimental protocol Thoracic 3. With the expansion of the PV, arterial and right atrial pressure returned to control value and sodium excretion gradually rose. At the same time, PRA and PA decreased to normal. Release of the constriction (inverted arrow) was accompanied by a fall in caval pressure and an initial rise in arterial and right atrial pressures during reabsorption of ascites and edema. The animal excreted 265 meq of sodium in the first 24 h after release and PV fell by 400 ml, while body weight decreased approximately 1.5 kg. In one animal (Fig. 2 ) the circulatory impairment was so severe that arterial and right atrial pressures were -not restored. This enabled us to examine the response of the RAA system in an animal unable to compensate adequately. In contrast to the response of the dog illustrated in Fig. 1 , PRA and PA remained elevated throughout the 2-wk period of caval constriction; PRA and PA were 12 and 14 times control value, respectively, when the constriction was released. Although sodium retention was nearly complete during the entire experiment, and body weight increased 6 kg, PV did not increase. However, after deflation of the cuff, PV rose 50% during the reabsorption of the ascites and edema, and BP increased from 80 to 110 mm Hg.
Acute converting enzyme blockade during thoracic inferior vena caval constriction. The previous data indicate that PRA (and by inference angiotensin II) is elevated early in the development of congestive failure. To determine the physiologic significance of the elevated angiotensin II in the maintenance of arterial pressure, single injections of the CEI were given on sequential days in two of the chronic dogs. In the normal animal, intravenous injection of 5 mg of the nonapeptide causes no change in arterial pressure, but blocks the usual pressor response to angiotensin I; the response to angiotensin II is unaltered. Fig. 3 illustrates the effects of acute converting enzyme blockade during TIVC constriction.
The experiment was similar to that shown in Fig. 1 Chronic converting enzyme blockade during thoracic inferior vena caval constriction. The previous experiments demonstrate the elevated levels of PRA and angiotensin II are important for the maintenance of arterial pressure during the development of congestive failure. To determine whether an animal can restore and maintain blood pressure when subjected to the circulatory impairment of caval constriction in the absence of generation of angiotensin II, a constant infusion of the CEI was given to three dogs. Fig. 4 illustrates the effect of chronic blockade by the CEI for 3 days during TIVC constriction. The animal with chronic inhibitor infusion tolerated only the initial constriction which increased inferior vena caval pressure by only 5 slightly near the end of the infusion when PRA exceeded 12 ng/ml per h, suggesting that blockade may have been incomplete at this time. In the normal dog after caval constriction, urinary sodium excretion fell to levels of < 5 meq/day, with 90% of dietary sodium retained; in the chronically blocked animal, urinary sodium excretion was reduced to an average of 25 meq/ day, with only 60% of intake retained (Table II) . Consequently, despite more severe and persistent hypotension during blockade, 30% less dietary sodium was retained in the blocked animals during the CEI infusion. On the other hand, it should be noted that two-thirds of the sodium could be retained without a rise in plasma angiotensin II and aldosterone. As shown in Table II , the increase in PV was also less in the blocked animal. Urinary potassium concentrations did not change significantly. During the period of infusion (3-5 days) no ascites was detected by abdominal tap and pitting edema was not present. Thus, when the generation of angiotensin II was suppressed by the CEI, dogs with moderate TIVC constriction were unable to restore arterial pressure during the 3-5-day infusion period. During chronic infusion in control experiments, no significant changes were noted in the measured parameters. Pulmonary artery constriction. Four experiments were performed in three dogs and the data are summarized in Table III . Under the conditions of these experiments, right-sided congestive heart failure developed over the course of several days, with the presence of ascites and edema. While right atrial pressure rose, left atrial and arterial pressures were significantly reduced. Although the increases in PRA and PA were much smaller than those observed with caval constriction, the changes in salt and water balance, and PV were comparable in the two series. By the 8th to 10 day after pulmonary artery constriction, aortic pressure was restored to normal, as was left atrial pressure, PRA, PA, and sodium excretion. In one animal pulmonary stenosis severe enough to prevent restoration of BP was induced. In this experiment aortic pressure fell to 60 mm Hg and remained at least 10 mm Hg below control for the entire period of stenosis (14 days). PRA rose to a peak value of 11.1 ng/ml per h by day 4 and was still 7.6 ng/ml per h before the release of the constriction. PA rose to a peak of 290 pg/ml by day 4 and was still 50 pg/ml at the end of the constriction. After the constriction, sodium retention was virtually complete for the entire period; water intake increased with a marked increase in body weight (4.1 kg 
DISCUSSION
To understand the role of the RAA system in the development of congestive failure, the natural history of the syndrome must be studied from the onset of the cardiovascular insult through the period of reflex compensation and subsequent attainment of a new steady state. In man, because of the long life history of the disease, it has not been feasible to perform such a study. As a result, the sequential changes in the RAA system in congestive heart failure in man are not well defined. Previous attempts in the experimental animal to define a role of the RAA system have often been episodic or have been complicated by anesthesia, surgery, and traumatic experimental procedures. In our laboratory, congestive heart failure was previously induced by the surgical production of tricuspid insufficiency followed by pulmonary artery stenosis. The animals were first studied several weeks later after recovery from surgery. At this time many of the important compensatory changes had already taken place. To circumvent these problems in the current study, the trained animals were chronically catheterized and inflatable cuffs were placed on the pulmonary artery and TIVC. No measurements were made until the animals were fully recovered.
The sequential data obtained in these trained conscious dogs provide evidence for an essential role in the RAA system in the genesis of congestive failure and demonstrate that chronic blockade of the system markedly impairs the ability of the animal to compensate. We have defined compensation as a restoration of arterial pressure with normal PRA and PA levels. The circulatory impairment caused by the imposition of TIVC or pulmonary artery constriction initiates a series of compensatory responses, among which is a rise in PRA and, by inference, angiotensin II. This elevation in angiotensin II is important for the restoration of arterial pressure in the early stages of failure, indicated by the marked fall in pressure when the CEI is injected during this period. When the converting enzyme is blocked chronically by a constant infusion of the inhibitor, more severe hypotension follows constriction and hypotension persists throughout the period of infusion, which is further evidence for the importance of the elevation of angiotensin II. Johnson and Davis (19) have reported similar data in congestive failure using the [Sar1, Ala8] angiotensin II analog. The (20) , Fernandez (21) , and Simpson and Routtenberg (22) have provided evidence that the angiotensin II may act as a dipsogenic factor important in the maintenance of body fluid balance.
As a result of the sodium and water retention, intravascular and extravascular fluid volume expand.
The increased PV is apparently an essential compensa-tory response in congestive failure. As a consequence o: the increased PV, ventricular end-diastolic volume is restored or elevated, augmenting ventricular performance. When expansion of the PV was sufficient to restore arterial pressure, and PRA was again normal, injection of the CEI had no effect on arterial pressure, indicating that angiotensin II no longer played a significant role in the maintenance of arterial pressure. With further expansion of the extravascular fluid volume, the ascites and edema characteristic of right-sided congestive failure developed.
In the animals that were unable to compensate, PV was not significantly increased, although ascites and edema were more severe than in the compensated animal. Similar data were reported by Ross et al. (23) who found that dogs with severe congestive failure (tricuspid insufficiency and pulmonic stenosis) had normal or reduced total blood volume. These observations on PV in the compensated vs. the uncompensated animal may help to explain the variable results reported in patients with congestive heart failure.
Release of the TIVC constriction was invariably associated with a marked but transient rise in arterial pressure; right atrial pressure increased while inferior vena caval pressure decreased. Arterial and atrial pressures stabilized at control values within 48-72 h. The effects on PRA and PA depended upon the levels before release. If PRA and PA levels were elevated, they fell promptly upon release; if they were at control levels no significant change was noted. In the animals that were able to compensate, PV fell to control levels within 72 h; in animals with severe failure PV initially rose during the mobilization of ascites and edema and then gradually fell to control. Diuresis and natriuresis invariably followed the release of the constriction, the magnitude depending upon the total amount of sodium and water retained during the period of constriction. The same general pattern followed pulmonary artery release except that right atrial pressure fell while left atrial pressure increased with release.
The mechanisms controlling renin release in congestive failure have not been well defined. By comparing the changes in PRA after TIVC constriction with that observed after pulmonary artery constriction, some important clues have emerged, particularly as regards the relative role of high and low pressure receptors. With TIVC constriction BP fell and PRA increased markedly, suggesting the rise in PRA may be related to a fall in arterial pressure through activation of the renal baroceptor mechanism as proposed by Witty et al. (24) . When a comparable drop in arterial pressure was induced by pulmonary artery constriction the rise in PRA was much less. Since the fall in arterial pressure was similar in both models (a 10-15- (25) (26) (27) (28) . In the present experiments with TIVC constriction, right and left atrial pressures were reduced, whereas with pulmonary artery constriction right atrial pressure increased while left atrial pressure was decreased. In the TIVC experiments PRA returned to control level simultaneously with the restoration of atrial pressures; arterial pressures were usually back to normal several days earlier, probably as a result of the high levels of circulating angiotensin II. After pulmonary artery constriction, PRA returned to normal when left atrial pressure was back to control level. Thus, the high PRA noted with TIVC constriction may result from the combined effects of renal artery hypotension and reflex neurogenic stimuli resulting from decreased cardiopulmonary pressures. In contrast, with pulmonary artery constriction, the fall in the left atrial pressure may be counterbalanced by the rise in right atrial pressure. Consequently, the major stimulus to renin release with pulmonary artery constriction may be the renal artery hypotension. In support of such a view is the quantitatively similar rise in PRA observed when renal perfusion pressure was reduced to comparable levels by either pulmonary artery or renal artery constriction (29) .
In summary, the compensatory responses to mild TIVC or pulmonary artery constriction may be divided into an early and late stage. In the early stage of TIVCC, arterial and atrial pressures fell; after pulmonary artery constriction, right atrial pressure rose while left atrial pressure fell. PRA, angiotensin II generation, and PA increased. The elevation of systemic angiotensin II was essential for the maintenance of arterial pressure; intrarenally, the increase in angiotensin II and in aldosterone may be important in the retention of sodium and water. As a consequence of the salt and water retention, intravascular and extravascular fluid volumes expanded. In the later stage, if compensation was adequate, arterial and atrial pressures returned toward normal and PRA and PA fell to control levels. Sodium excretion was restored and the animal with venous congestion, ascites, and edema reached a new steady state. As a result of the expanded PV, ventricular performance was restored or augmented and the elevated levels of angiotensin II were no longer essential for the maintenance of arterial pressure. When circulatory impairment was severe or compensation was inadequate, PRA and PA remained elevated during the entire period of constriction. A single injection of the CEI caused a fall in arterial pressure when PRA was elevated, but produced no change when PRA was normal. Chronic infusion of the CEL, which suppressed the generation of angiotensin II and in turn a rise in aldosterone, markedly impaired the ability of the animal to compensate. After constriction with CEI, severe hypotension persisted and the ability to conserve sodium and water was diminished. By examination of the sequential changes in the RAA system during the initiation and maintenance of congestive failure, the variability in PRA and PA levels reported in the literature may now be understood. Early in the development of the failure they may be elevated; during the later or compensated stage they may be normal. The particular PRA or PA level observed in congestive failure depends, then, upon the state of compensation.
We conclude that the RAA system plays an essential homeostatic role in the development of congestive failure and is important for both restoration of arterial pressure and the expansion of intravascular volume. Secondly, changes in cardiopulmonary pressures may be important in the regulation of renin secretion. Finally, the nonapeptide converting enzyme inhibitor has proven to be a useful pharmacologic tool to define the role of the RAA system in the development of congestive failure.
